Frontlight ResearchEarly access
WithdrawnPhase 2
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
Key facts
- Who runs it
- Y-mAbs Therapeutics
- Where
- Hong Kong, Russia, Singapore, and South Korea9 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 2 Dec 2021
- Expected to end
- Apr 2027
- Type of study
- Interventional
- Treatments tested
- Naxitamab
- GM-CSF
- Isotretinoin
- Record updated
- 1 September 2022
- Why it stopped
- Study terminated due to business priorities
Who can take part
- Age
- 1 year and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Documentet neuroblastoma at time of diagnosis defined as; Histopathology of solid tumor biopsy, or; Bone marrow aspirate or biopsy indicative of neuroblastoma plus high blood or urine catecholamine metabolite levels
- Documented high-risk disease at time of initial diagnosis defined as; MYNC-amplified at stage L2, M or MS (according to International Neuroblastoma Risk Group (INRG)) of any age or; MYCN-nonamplified with stage M (according to INRG) and diagnosed at ≥ 18 months of age or
- Patient must have completed frontline therapy, and achieved one of the following:; verified complete response according to INRC (bone marrow positive minimal residual disease is allowed as assessed by RTqPCR at site) after completion of induction and consolidation with or without autologous stem cell transplantation; Verified partial response according to INRC for primary site and soft tissue, bone, and bone marrow metastases at pre-autologous stem cell transplantation evaluation (i.e., myeloablative chemotherapy + autologous stem cell transplantation required as part of frontline regimen). Furthermore, bone marrow response must be with ≤ 5% tumor (of total nucleated cellular content) seen on any specimen from a bilateral bone marrow aspirate/biopsy and bone response must be with ≤ 3 areas of abnormal uptake on 123I-MIBG scintigraphy
- Age ≥ 12 months at trial enrollment
Who cannot take part
- Any systemic anti-cancer therapy, including chemotherapy, within 3 weeks prior to enrollment
- Autologous stem cell transplantation within 6 weeks prior to enrollment or ongoing toxicity caused by the autologous stem cell transplantation at the discretion of the Investigator
- Therapeutic 131I-MIBG within 6 weeks prior to enrollment
- Prior anti-GD2 therapy
- Verified progressive disease during induction or consolidation therapy
- Performance status of < 50% as per the Lansky scale (patients less than 16 years of age) or Karnofsky scale (patients aged 16 years or older)
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a single-arm, uncontrolled, international, multi-center, clinical,phase 2 trial, in patients ≥ 12 months of age with high-risk neuroblastoma in first remission. 120 patients will be enrolled to receive naxitamab + GM-CSF in combination with isotretinoin.
The group in the trial
- naxitamab + GM-CSF + isotretinoinTreatment being tested
8 cycles. Cycles 1+2 naxitamab + GM-CSF, cycles 3-5 naxitamab + GM-CSF + isotretinoin, cycles 6-8 isotretinoin
Treatment: Naxitamab, GM-CSF, and Isotretinoin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. An International, Open-Label,Uncontrolled, Single-Arm, Multicenter, Phase 2 Trial
- Record updated
- 1 September 2022